Annexon Investor Day: ANX007 Targets C1q in Dry AMD GA as Phase III Readout Nears Q4 [Yahoo! Finance]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
and visual function, a strategy Annexon argues is distinct from approved downstream C3/C5 inhibitors that target lesion/RPE atrophy. In the 270-patient Phase II ARCHER study the primary FAF lesion-growth endpoint was not met, but OCT showed reduced ellipsoid-zone loss (up to 27–59% in nearer-foveal regions) and functional analyses reported a strong signal for vision protection (reported ~73% risk reduction for confirmed 15-letter BCVA loss with monthly dosing), with no new major safety signals. The global ARCHER II Phase III (659 patients, 2:1 randomization) incorporated protocol changes to enrich events—excluding very low baseline vision, increasing subfoveal lesion representation, and extending the primary endpoint to 15 months—and topline results are expected in Q4 this year. Interested in Annexon, Inc.? Here are five stocks we like better. Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for vonoprument (ANX
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Annexon (ANNX) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.MarketBeat
- Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference [Yahoo! Finance]Yahoo! Finance
- Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
- Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy [Yahoo! Finance]Yahoo! Finance
ANNX
Earnings
- 11/10/25 - Miss
ANNX
Sec Filings
- 3/12/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- ANNX's page on the SEC website